A Single-Center, Phase 2 Study Evaluating Bilastine Ophthalmic Solution in the CAC® Model
| Status: | Completed |
|---|---|
| Conditions: | Allergy, Ocular |
| Therapuetic Areas: | Ophthalmology, Otolaryngology |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 10/28/2018 |
| Start Date: | July 20, 2017 |
| End Date: | October 11, 2017 |
A Single-Center, Double-Masked, Randomized, Vehicle-Controlled, Phase 2, Dose Ranging Evaluation of the Effectiveness of Bilastine Ophthalmic Solution (0.2%, 0.4%, and 0.6%) Compared to Vehicle for the Treatment of Allergic Conjunctivitis in the Conjunctival Allergen Challenge (Ora-CAC®) Model
To evaluate the efficacy of Bilastine Ophthalmic Solution (0.2%,0.4%,0.6%) compared to
vehicle for the treatment of the signs and symptoms of allergic conjunctivitis
vehicle for the treatment of the signs and symptoms of allergic conjunctivitis
Key Inclusion Criteria:
- be at least 18 years old
- be willing and able to avoid all disallowed medications and contact lenses
- must have a pregnancy test if of childbearing potential
- must be able to read an eye chart from 10 feet away
Key Exclusion Criteria:
- must not have any allergies to the study medications
- must not have any ocular or non ocular condition that investigator feels will
interfere with study parameters
- must not have used immunotherapy in the last 2 years
- must not have used an investigational drug or device in the past 30 days or
concurrently enrolled in another investigational trial
We found this trial at
1
site
Click here to add this to my saved trials
